Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab

International Journal of Cardiology

Volumn 101, Issue 2, 2005, Pages 249-255

  Ray, M J ^a   Walters, D L ^a   Bett, J N H ^a   Cameron, J ^a   Wood, P ^a   Aroney, C N ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Angioplasty; Inhibitors; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; TROPONIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MONOCYTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CELL AGGREGATION; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MONOCYTES; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TROPONIN I;

EID: 18344396063     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.03.033     Document Type: Article

References (39)

1. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344:2001;1879-1887
2. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 354:1999;708-715
3. Harding S.A., Walters D.L., Palacios I.F., Oesterle S.N. Adjunctive pharmacotherapy for coronary stenting. Curr. Opin. Cardiol. 16:2001;293-299
4. Freedman J.E., Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 105:2002;2130-2132
5. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143
6. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:1998;425-428
7. Furie B., Furie B.C., Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb. Haemost. 86:2001;214-221
8. Celi A., Pellegrini G., Lorenzet R., et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8767-8771
9. McEver R.P. P-selectin and PSGL-1: exploiting connections between inflammation and venous thrombosis. Thromb. Haemost. 87:2002;364-365
10. Shebuski R.J., Kilgore K.S. Role of inflammatory mediators in thrombogenesis. J. Pharmacol. Exp. Ther. 300:2002;729-735
11. Weyrich A.S., Elstad M.R., McEver R.P., et al. Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest. 97:1996;1525-1534
12. Furman M.I., Kereiakes D.J., Krueger L.A., et al. Leukocyte-platelet aggregation, platelet surface P-selectin and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am. Heart J. 142:2001;790-798
13. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 104:2001;1533-1537
14. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 344:2001;1888-1894
15. Hongo R.H., Ley J., Dick S.E., Yee R.R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. Cardiol. 40:2002;231-237
16. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch. Intern. Med. 157(21):1997;2413-2446
17. Report of a WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications - Part 1: diagnosis and classification of diabetes mellitus. 1999;World Health Organisation, Geneva
18. National Heart Foundation of Australia and The Cardiac Society of Australia and New Zealand Australian Lipid Management Guidelines. MJA. 175:2001;S57-S88
19. National Heart Foundation of Australia and The Cardiac Society of Australia and New Zealand Australian Management of Unstable Angina Guidelines. MJA. 175:2001;S57-S88
20. Shattil S.J., Cunningham M., Hoxie J.A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 70:1987;307-315
21. Schmitz G., Rothe G., Ruf A., et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb. Haemost. 79:1998;885-896
22. Ray M., Walters D.L., Bett N., Cameron J., Wood P., Aroney C.N. Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard dose abciximab therapy during percutaneous coronary intervention. Card. Catheter. Interv. 62:2004;150-154
23. Feinstein A.R. Inner zones and spreads. Principles of medical statistics. 2002;65 Chapman & Hall, Boca Raton
24. Furman M.I., Benoit S.E., Barnard M.R., Valeri C.R., Borbone M.L., Becker R.C., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 31:1998;352-358
25. Kleiman N.S., Grazeiadei N., Maresh K., Taylor R.J., Frederick B., Lance E.T., et al. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. Am. Heart J. 140:2000;492-503
26. Bhatt D.L., Topol E.J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 284:2000;1549-1558
27. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 352:1998;87-92
28. Ndoko S., Poujol C., Combrie R., Nurden A., Nurden P. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes. Thromb. Haemost. 87:2002;317-322
29. Bihour C., Durrieu-Jais C., Macchi L., Poujol C., Coste P., Besse P., et al. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler. Thromb. Vasc. Biol. 19:1999;212-219
30. Furman M.I., Barnard M.R., Krueger L.A., Fox M.L., Shilale E.A., Lessard D.M., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J. Am. Coll. Cardiol. 38:2001;1002-1006
31. Kirchhofer D., Riederer M.A., Baumgartner H.R. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood. 89:1997;1270-1278
32. Sarma J., Laan C.A., Alam S., Jha A., Fox K.A., Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 105:2002;2166-2171
33. Hansen P.R. Role of neutrophils in myocardial ischemia and reperfusion. Circulation. 91:1995;1872-1885
34. Kizer J.R., Muttrej M.R., Matthai W.H., McConnell J., Nardone H., Sonel A.F., et al. Role of troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur. Heart J. 24:2003;1314-1322
35. Bonz A., Lengenfelder B., Strotmann J., Held S., Turschner O., Harre K., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J. Am. Coll. Cardiol. 40:2002;662
36. May A.E., Neumann F.J., Gawaz M., Ott I., Walter H., Schomig A. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur. Heart J. 18:1997;1913-1920
37. Myers D., Wrobleski S., Londy F., Fex B., Hawley A., Schaub R., et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb. Haemost. 87:2002;374-382
38. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J. Am. Coll. Cardiol. 28:1996;345-353
39. Mickelson J.K., Ali M.N., Kleiman N.S., et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. 33:1999;97-106